Afferent arteriolar vasodilator effect of adenosine predominantly involves adenosine A2B receptor activation

American Journal of Physiology - Renal Physiology

Volumn 299, Issue 2, 2010, Pages

  Feng, Ming Guo ^a   Navar, L Gabriel ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine receptor antagonists; Afferent arterioles; Kidney; Renal microcirculation; Vascular biology

Indexed keywords

2 ANILINOADENOSINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR;

ANIMAL EXPERIMENT; ARTERIOLE; ARTICLE; BLOOD VESSEL DIAMETER; BLOOD VESSEL TONE; CONCENTRATION RESPONSE; CONTROLLED STUDY; KIDNEY CIRCULATION; MALE; MICROCIRCULATION; NEPHRON; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; VASODILATATION; VIDEORECORDING;

EID: 77955351657     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00149.2010     Document Type: Article

References (48)

1. Al-Mashhadi RH, Skøtt O, Vanhoutte PM, Hansen PB. Activation of A(2) adenosine receptors dilates cortical efferent arterioles in mouse. Kidney Int 75: 793-799, 2009.
2. Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Monopoli A, Ongini E, Varani K, Borea PA. 7-Substituted 5-amino-2-(2-furyl)pyrazolo[ 4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. J Med Chem 45: 115-126, 2002.
3. Bell TD, Welch WJ. Regulation of renal arteriolar tone by adenosine: novel role for type 2 receptors. Kidney Int 75: 769-771, 2009.
4. Berthold H, Just A, Kirchheim HR, Osswald H, Ehmke H. Renal hemodynamic responses to exogenous and endogenous adenosine in conscious dogs. J Physiol 510: 321-330, 1998. (Pubitemid 28351946)
5. Beukers MW, van Oppenraaij J, van der Hoorn PP, Blad CC, den Dulk H, Brouwer J, Ijzerman AP. Random mutagenesis of the human adenosine A2B receptor followed by growth selection in yeast. Identification of constitutively active and gain of function mutations. Mol Pharmacol 65: 702-710, 2004.
6. Burnstock G. Purinergic receptors in the heart. Circ Res 46: I175-I182, 1980.
7. Carroll MA, Doumad AB, Li J, Cheng MK, Falck JR, McGiff JC. Adenosine 2A receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway. Am J Physiol Renal Physiol 291: F155-F161, 2006.
8. 2A receptors. Br J Pharmacol 141: 441-448, 2004.
9. Dobrowolski L, Kompanowska-Jezierska E, Walkowska A, Sadowski J. Sodium intake determines the role of adenosine A2 receptors in control of renal medullary perfusion in the rat. Nephrol Dial Transplant 22: 2805-2809, 2007. (Pubitemid 350093437)
10. Feng MG, Navar LG. Adenosine A2 receptor activation attenuates afferent arteriolar autoregulation during adenosine receptor saturation in rats. Hypertension 50: 744-749, 2007.
11. 2+ channels in afferent and efferent arterioles. Am J Physiol Renal Physiol 290: F873-F879, 2006.
12. Feng MG, Li M, Navar LG. T-type calcium channels in the regulation of afferent and efferent arterioles in rats. Am J Physiol Renal Physiol 286: F331-F337, 2004.
13. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527-552, 2001.
14. Fredholm BB, Irenius E, Kull B, Schulte G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in chinese hamster ovary cells. Biochem Pharmacol 61: 443-448, 2001.
15. Fredholm BB, Abbracchio MP, Burnstock G, Dubyak GR, Harden TK, Jacobson KA, Schwabe U, Williams M. Toward a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci 18: 79-82, 1997.
16. 1 MF-2 smooth muscle cells. Mol Pharmacol 38: 660-666, 1990.
17. Guan ZR, Osmond DA, Inscho EW. Purinoceptors in the kidney. Exp Biol Med (Maywood) 232: 715-726, 2007.
18. Hansen PB, Hashimoto S, Oppermann M, Huang Y, Briggs JP, Schnermann J. Vasoconstrictor and vasodilator effects of adenosine in the mouse kidney due to preferential activation of A1 or A2 adenosine receptors. J Pharmacol Exp Ther 315: 1150-1157, 2005.
19. Hashimoto S, Huang Y, Briggs J, Schnermann J. Reduced autoregulatory effectiveness in adenosine 1 receptor-deficient mice. Am J Physiol Renal Physiol 290: F888-F891, 2006.
20. Imig JD, Falck JR, Inscho EW. Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. Br J Pharmacol 127: 1399-1405, 1999.
21. Jackson EK, Zhu C, Tofovic SP. Expression of adenosine receptors in the preglomerular microcirculation. Am J Physiol Renal Physiol 283: F41-F51, 2002. (Pubitemid 34680470)
22. Ji X, Kim YC, Ahern DG, Linden J, Jacobson KA. [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. Biochem Pharmacol 161: 657-663, 2001.
23. Kim YC, Ji X, Melman N, Linden J, Jacobson KA. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem 43: 1165-1172, 2000.
24. Lee HT, Emala CW. Characterization of adenosine receptors in human kidney proximal tubule (HK-2) cells. Exp Nephrol 10: 383-392, 2002. (Pubitemid 36151254)
25. Modlinger PS, Welch WJ. Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 12: 497-502, 2003.
26. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev 76: 425-536, 1996.
27. 2a receptors on renal microvascular reactivity. Am J Physiol Renal Physiol 280: F406-F414, 2001.
28. Olah, & Stiles ME, GL. The role of receptor structure in determining adenosine receptor activity. Pharmacol Ther 85: 55-75, 2000.
29. Ongini E, Fredholm BB. Pharmacology of adenosine A2A receptors. Trends Pharmacol Sci 17: 364-372, 1996.
30. Osswald H, Spielman WS, Knox FG. Mechanism of adenosine-mediated decreases in glomerular filtration rate in dogs. Circ Res 43: 465-469, 1978.
31. 1 receptors: a complicating factor in quantitative autoradiography. J Neurochem 58: 941-950, 1992.
32. Pawlowska D, Granger JP, Knox FG. Effects of adenosine infusion into renal interstitium on renal hemodynamics. Am J Physiol Renal Fluid Electrolyte Physiol 252: F678-F682, 1987.
33. 1 adenosine receptors: occupation of cryptic binding sites by endogenous vesicular adenosine. Mol Pharmacol 42: 765-772, 1992.
34. Satoh A, Satoh K, Masamune A, Yamagiwa T, Shimosegawa T. Activation of adenosine A2a receptor pathway reduces leukocyte infiltration but enhances edema formation in rat caerulein pancreatitis. Pancreas 24: 75-82, 2002.
35. Spielman WS, Thompson CI. A proposed role for adenosine in the regulation of renal hemodynamics and renin release. Am J Physiol Renal Fluid Electrolyte Physiol 242: F423-F435, 1982. (Pubitemid 12099166)
36. Spielman WS, Britton SL, Fiksen-Olsen MJ. Effect of adenosine on the distribution of renal blood flow in dogs. Circ Res 46: 449-456, 1980.
37. Sun D, Samuelson LC, Yang T, Huang Y, Paliege A, Saunders T, Briggs J, Schnermann J. Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci USA 98: 9983-9988, 2001.
38. Tagawa H, Vander AJ. Effects of adenosine compounds on renal function and renin secretion in dogs. Circ Res 26: 327-338, 1970.
39. Thorsell A, Johnson J, Heilig M. Effect of the adenosine A2a receptor antagonist 3,7-dimethyl-propargylxanthine on anxiety-like and depression-like behavior and alcohol consumption in Wistar Rats. Alcohol Clin Exp Res 31: 1302-1307, 2007.
40. Tostes RC, Giachini FR, Carneiro FS, Leite R, Inscho EW, Webb RC. Determination of adenosine effects and adenosine receptors in murine corpus cavernosum. J Pharmacol Exp Ther 322: 678-685, 2007. (Pubitemid 47105776)
41. Vallon V, Mühlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev 86: 901-940, 2006.
42. Vallon V, Mühlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev 86: 901-940, 2006.
43. Vallon V, Osswald H. Adenosine receptors and the kidney. Handb Exp Pharmacol 193: 443-470, 2009.
44. Vitzthum H, Weiss B, Bachleitner W, Krämer BK, Kurtz A. Gene expression of adenosine receptors along the nephron. Kidney Int 65: 1180-1190, 2004.
45. Weaver DR, Reppert SM. Adenosine receptor gene expression in rat kidney. Am J Physiol Renal Fluid Electrolyte Physiol 263: F991-F995, 1992.
46. Yang M, Soohoo D, Soelaiman S, Kalla R, Zablocki J, Chu N, Leung K, Yao L, Diamond I, Belardinelli L, Shryock JC. Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 375: 133-144, 2007.
47. Zocchi C, Ongini E, Conti A, Monopoli A, Negretti A, Baraldi PG, Dionisotti S. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist. J Pharmacol Exp Ther 276: 398-404, 1996.
48. Zou AP, Wu F, Li PL, Cowley AW Jr. Effect of chronic salt loading on adenosine metabolism and receptor expression in renal cortex and medulla in rats. Hypertension 33: 511-516, 1999. (Pubitemid 29065712)